Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis

被引：0
|
作者：
Gulati, Shuchi [1 ]
Elsisi, Zizi [2 ]
Deoghare, Smruti [2 ]
Eckman, Mark [2 ]
机构：
[1] Univ Cincinnati, Vontz Ctr Mol Studies, Cincinnati, OH USA
[2] Univ Cincinnati, Cincinnati, OH USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124756
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
328
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma
    Daniel Dubinski
    Sae-Yeon Won
    Martin Voss
    Fee Keil
    Wolfgang Miesbach
    Bedjan Behmanesh
    Max Dosch
    Peter Baumgarten
    Joshua D. Bernstock
    Volker Seifert
    Thomas M. Freiman
    Florian Gessler
    Neurosurgical Review, 2022, 45 : 451 - 457
  • [32] Comparison of Switching to Direct Oral Anticoagulants and Continuous Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism in Taiwan
    Kang, Wei
    Shen, Chin-Yao
    Cheng, Michael Chun-Yuan
    Yan, Vincent Kc
    Wei, Yue
    Li, Tung Hiu
    Huang, Caige
    Lai, Edward Chia-Cheng
    Wong, Ian Chi Kei
    Chan, Esther W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 77 - 77
  • [33] Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma
    Dubinski, Daniel
    Won, Sae-Yeon
    Voss, Martin
    Keil, Fee
    Miesbach, Wolfgang
    Behmanesh, Bedjan
    Dosch, Max
    Baumgarten, Peter
    Bernstock, Joshua D.
    Seifert, Volker
    Freiman, Thomas M.
    Gessler, Florian
    NEUROSURGICAL REVIEW, 2022, 45 (01) : 451 - 457
  • [34] Direct Oral Anticoagulants Compared With Low Molecular Weight Heparin and Vitamin K Antagonists in the Management of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis
    Mir, Ali
    Rahman, Mohammed F.
    Ragab, Khaled M.
    Elsayed, Sarah M.
    Fathallah, Ahmed H.
    Hagrass, Abdulrahman I.
    Kamal, Ibrahim
    Farooq, Waseem
    Bahuva, Ronak
    Page, Brian
    CIRCULATION, 2022, 146
  • [35] The anticoagulants rivaroxaban and low molecular weight heparin prevent PICC-related upper extremity venous thrombosis in cancer patients
    Lv, Shoutian
    Liu, Yongmei
    Wei, Gang
    Shi, Xueyan
    Chen, Shaoping
    Zhang, Xuehui
    MEDICINE, 2019, 98 (47)
  • [36] Direct oral anticoagulants for the treatment of Mondor's disease not responding to low-molecular weight heparin
    Serrao, Alessandra
    Lucani, Benedetta
    Baldacci, Erminia
    Fiori, Luciano
    Chistolini, Antonio
    PHLEBOLOGY, 2020, 35 (09) : 734 - 735
  • [37] PERIOPERATIVE MANAGEMENT OF PATIENTS IN TREATMENT WITH DIRECT ORAL ANTICOAGULANTS: USE OF POSTOPERATIVE LOW MOLECULAR WEIGHT HEPARIN
    Campoy Castano, D.
    Flores Aparco, K.
    Canals Pernas, T.
    Velasquez Escandon, C.
    Bastidas Mora, G.
    Ruiz de Gracia, S.
    Comai, A.
    Artaza Minano, G.
    Ene, G.
    Subira Caselles, M.
    Salinas Argente, R.
    Olivera Sumire, P.
    HAEMATOLOGICA, 2019, 104 : 124 - 125
  • [38] Direct acting oral anticoagulants versus low molecular weight heparin for primary thromboprophylaxis in cancer patients
    Mendez, Natalia
    Norambuena, Constanza
    Silva, Symon
    Lopez, Valentin
    MEDWAVE, 2021, 21 (04):
  • [39] Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis
    López-Beret, P
    Orgaz, A
    Fontcuberta, J
    Doblas, M
    Martinez, A
    Lozano, G
    Romero, A
    JOURNAL OF VASCULAR SURGERY, 2001, 33 (01) : 77 - 90
  • [40] Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism
    Coleman, Craig, I
    Caroti, Kimberly Snow
    Abdelgawwad, Khaled
    Psaroudakis, George
    Rivera, Marcela
    Brobert, Gunnar
    Cohen, Alexander T.
    Khorana, Alok A.
    Becattini, Cecilia
    Lee, Agnes Y.
    Ekbom, Anders
    Carrier, Marc
    BLOOD, 2022, 140 : 11368 - 11369
12345